A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Completed · Phase 3

Conditions studied: Diabetes Mellitus, Type 2

In brief

The purpose of this study is to assess the effectiveness of the co-administration of canagliflozin and metformin extended release (XR) compared with canagliflozin alone, and metformin XR alone in patients with type 2 diabetes mellitus with inadequate control despite treatment with diet and exercise. The safety and tolerability of canagliflozin will also be assessed.

Key facts

Study ID

NCT01809327

Run by

Janssen Research & Development, LLC

People needed

1186

Starts

2013-06-04

Expected to finish

2014-12-02

Last updated by the study team

2017-07-11

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have type 2 diabetes mellitus with inadequate glycemic control on diet and exercise
• Not on antihyperglycemic agent therapy (at least 12 weeks before screening) and have a screening visit fingerstick glycated hemoglobin (HbA1c) of more than or equal to 7 percent and less than or equal to 12.5 percent
• Have a screening visit HbA1c of more than or equal to 7.5 percent and less than or equal to 12 percent as determined by the central laboratory
• Must have a fasting plasma glucose of less than or equal to 300 mg/dL (16.7 mmol/L) prior to randomization
• Must have a fasting fingerstick glucose of greater than 120 mg/dL (6.7 mmol/L) performed at home or at the study center prior to randomization

You may not qualify if…

• History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
• Fasting C-peptide less than 0.70 ng/mL (0.23 nmol/L) in participants for whom the investigator cannot reasonably exclude T1DM based upon clinical evaluation
• Repeated (2 or more over a 1 week period) fasting self-monitored blood glucose measurements more than 300 mg/dL (16.7 mmol/L) prior to randomization, despite reinforcement of diet and exercise counseling
• History of hereditary glucose-galactose malabsorption or primary renal glucosuria
• Has history of, or currently active, illness considered to be clinically significant by the Investigator or any other illness that the Investigator considers should exclude the patient from the study or that could interfere with the interpretation of the study results

Where it is running

• Study site — Phoenix, Arizona, United States
• Study site — Encinitas, California, United States
• Study site — Newport Beach, California, United States
• Study site — Northridge, California, United States
• Study site — Norwalk, California, United States
• Study site — Rancho Cucamonga, California, United States
• Study site — Walnut Creek, California, United States
• Study site — Denver, Colorado, United States
• Study site — Northglenn, Colorado, United States
• Study site — Hialeah, Florida, United States
• Study site — Miami, Florida, United States
• Study site — New Port Richey, Florida, United States
• Study site — Opa-locka, Florida, United States
• Study site — Perry, Georgia, United States
• Study site — Evansville, Indiana, United States
• Study site — Mandeville, Louisiana, United States
• Study site — Metairie, Louisiana, United States
• Study site — Sunset, Louisiana, United States
• Study site — Flint, Michigan, United States
• Study site — Kalamazoo, Michigan, United States
• Study site — Royal Oak, Michigan, United States
• Study site — Troy, Michigan, United States
• Study site — Olive Branch, Mississippi, United States
• Study site — Picayune, Mississippi, United States
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.